Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2015-12-21
|
| gptkbp:ATCCode |
B01AC27
|
| gptkbp:CASNumber |
475086-01-2
|
| gptkbp:chemicalFormula |
C26H32N4O4S
|
| gptkbp:form |
gptkb:tablet
|
| gptkbp:genericName |
selexipag
|
| https://www.w3.org/2000/01/rdf-schema#label |
Uptravi
|
| gptkbp:indication |
reduce risk of disease progression in PAH
|
| gptkbp:KEGGID |
D10413
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Janssen_Pharmaceuticals
|
| gptkbp:mechanismOfAction |
prostacyclin receptor agonist
|
| gptkbp:pregnancyCategory |
N (Not classified)
|
| gptkbp:prescriptionStatus |
Rx-only
|
| gptkbp:PubChem_CID |
gptkb:DB11363
CHEMBL2105751 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea headache flushing myalgia jaw pain |
| gptkbp:UNII |
Y72T1J1FZ2
|
| gptkbp:usedFor |
pulmonary arterial hypertension
|
| gptkbp:bfsParent |
gptkb:Actelion
|
| gptkbp:bfsLayer |
6
|